Biologische Therapien und Krebs - the European Oncology Nursing ...

8
Peters J, Dimond E, Jenkins J. Clinical applications of genetic technologies to cancer care. Cancer Nurs
1997;20:359–77.
Rosenberg SA, editor. Principles and practice of the biologic therapy of cancer. 3rd ed. Philadelphia:
Lippincott Williams and Wilkins, 2000.
Trahan Rieger P. Biotherapy. Sudbury, MA, USA: Jones and Bartlett International, 1995.
Tranin AS, editor. Genetics and cancer. Semin Oncol Nurs 1997;13(2):67.
Zytokine
Atkins MB, Mier JW, editors. Applications of interleukin-2. New York: Marcel Dekker, 1998.
Cantell C. The story of interferon. World Scientific Publishing, 1998.
Klastersky J, Schimpff SC, Senn H-J, editors. Handbook of supportive care in cancer. New York:
Marcel Dekker, 1998.
Lindenmann J, Schleuning WD, editors. Interferon: the dawn of recombinant protein drugs. Berlin: Springer
Verlag, 1999.
Mandelli F, Arcese W, Avvisati G. The interferons in hematological malignancies. Baillieres Clin Haematol
1994;7:91–113.
Morstyn G, Dexter TM, Foote M, editors. Filgrastim (R-metHuG-CSF) in clinical practice. New York:
Marcel Dekker, 1998.
Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694–704.
Wagstaff J. The role of interleukin-2 in the treatment of cancer patients. Dordrecht: Kluwer Academic, 1993.
Waxman JH, Balkwill FR. Interleukin-2. Oxford: Blackwell Science, 1992.
Wingard JR, Demetri GD, editors. Clinical applications of cytokines and growth factors (developments in
oncology, No. 80). Boston: Kluwer Academic, 1999.
Antikörper-Therapie
Baquiran DC, Dantis L, McKerrow J. Monoclonal antibodies: innovations in diagnosis and therapy. Semin
Oncol Nurs 1996;12:130–41.
Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin ® ) enhances
the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer
xenografts. Cancer Res 1998;58:2825–31.
Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized
anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J Clin Oncol 1996;14:737–44.
Böhme C. Anti-HER2 therapy: how to use Herceptin ® in clinical practice. Eur J Oncol Nurs 2000;4(Suppl.
1):30–6.
Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185 HER2 antibody for human cancer therapy.
Proc Natl Acad Sci USA 1992;89:4285–9.
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized
anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that
has progressed after chemotherapy for metastatic disease.
J Clin Oncol 1999;17:2639–48.
8.29